Spinraza’s sales were a bright spot in Biogen’s second-quarter earning call this month — and that’s very good news for the University of Massachusetts.
A university spokesperson could not confirm the exact amounts and Biogen (BIIB) did not respond to a request for comment. However, based on figures provided by one of the inventors, STAT estimated that the university has received about $10.5 million since the FDA approved the drug for spinal muscular atrophy in December 2016.
That much money is only a small percentage of the university system’s $3.3 billion budget for 2019. Spinraza licensing fees will likely be only about 1 percent of the medical school’s total revenue for 2019, projected to be $892 million.
About the Author Reprints
